Purpose of review Ubiquitously-expressed small GTPase Rap1 is a key modulator of integrin-and cadherin-regulated processes. In endothelium, Rap1 promotes angiogenesis and endothelial barrier function, acting downstream from cAMP-activated Rap1GEF, Epac. Recent in-vivo studies in mouse models have provided more information about the physiological role of Rap1 in vessel development and after birth under normal and pathologic conditions. Important molecular details of dynamic regulation of endothelial barrier are uncovered.
INTRODUCTION
Evolutionarily conserved and ubiquitously expressed small GTPase Rap1 has been well characterized as a key modulator of integrin-and cadherin-regulated processes. Spatio-temporally regulated by a network of guanine nucleotine exchange factors (GEFs) and GTPase activating protein (GAPs), in a contextspecific manner, GTP-bound Rap1 interacts with a number of effectors controlling integrin-mediated cell-ECM adhesion, cell-cell junction formation, and cellular polarity [1, 2] . In endothelium, Rap1 is a key positive regulator of angiogenesis [3, 4] and an important regulator of endothelial barrier [5] acting as a mediator of elevated cAMP/cAMP-dependent Rap1 GEF, Epac activation [6] . Recent research has increased the understanding of the role of Rap1 in vascular development, normal and pathological angiogenesis, and endothelial barrier enhancement under pathological conditions in vivo, and molecular mechanisms underlying dynamic regulation of endothelial barrier with a particular emphasis on the connection with Rho GTPases and the actomyosin cytoskeleton. Importantly, recent research uncovered a novel and critically important physiological role of Rap in regulation of nitric oxide release and endothelial function and implicated Rap1 as a key regulator of mechanotransduction in endothelial cells by regulation of shear stress-mediated signaling in response to flowing blood.
,9], defects in hematopoiesis, neurological and immune responses and defective angiogenesis [10, 11] , also present in endothelial lineage-restricted (Tie2-Cre) Rap1b knockouts [12] . Although the development of mice lacking single Rap1 isoform in the endothelium is normal, endothelial cell-restricted knockout of both isoforms leads to developmental abnormality and lethality of $50% embryos at mid-gestation, whereas the remaining embryos appear normal. However, all double knockout embryos die before E13.5, likely because of hemorrhage [13 & ]. Therefore, Rap1 in endothelium is indispensable for vascular stability and the formation of functional vasculature. Interestingly, mice with one Rap1a allele (EC-Rap1a
) exhibited embryonic hemorrhage and significantly reduced viability at weaning, a phenotype absent in mice with one remaining Rap1b allele (EC-Rap1a À/À Rap1b þ/À ), signifying relative importance of the Rap1b isoform for normal vessel formation. Remarkably, postdevelopment, deletion of both Rap1 isoforms does not have a deleterious effect on vessel permeability or gross vessel and cell-cell junction morphology [8 && ]. Therefore, Rap1 is not absolutely required for maintenance of existing cell-cell junctions and preservation of endothelial barrier.
Interestingly, murine endothelial cell-specific knockout of Ras-interacting protein 1 (Rasip1), a 104 kD effector of H-Ras, K-Ras, and Rap1 [14] , leads to a more severe vascular embryonic phenotype with focal hemorrhage and lethality because of vessels unable to sustain circulation beyond mid-gestation [15, 16 && ]. Implicated as a junctional effector of the Epac-Rap1 signaling axis, the Rasip1-ArhGAP-RhoA pathway had been previously suggested to regulate endothelial cell tubulogenesis and establishment of endothelial polarity [15] ; however, patent vessels are formed in EC-Rasip1 knockout mice, to collapse later in development [16 && ]. Therefore, unlike Rap1, Rasip1 is critical for early vasculogenesis.
Rap1 is also a positive regulator of angiogenesis in vivo (previously reviewed in refs. [3, 4] ), with an adaptor protein Afadin acting as one of its effectors. Afadin, a 205 kD adaptor molecule localized to cellcell junctions connects actin cytoskeleton with cell-cell junctional receptors. In addition to RA domain through which it binds Rap1 and a PDZ domain through which it interacts with transmembrane proteins [17] , afadin contains forkheadassociated and dilute domains, also shared with its relative, Rasip1 [14] .
Afadin regulates VEGF and S1P signaling and modulates postnatal retinal angiogenesis [18] , but is not essential for developmental endothelial angiogenesis [19 & ]. It is, however, essential for normal embryonic development of lymphatic vessels in mice as its deficiency in Tie2-Cre driven conditional knockout mice leads to severe subcutaneous edema, lymphatic vessel malformation, disruption of VEcadherin junctions, and embryonic lethality after day E15.5. Underlying the lymphangiogenic defects are disrupted VE-cadherin junctions in vivo and elevated Rho activity in lymphatic endothelial cells (but not vascular endothelial cells) in vitro [19 & ]. This suggests cell-type specificity of Afadin as a Rap1 effector.
In-vivo studies have defined physiological significance of Rap1 in endothelium: during development, Rap1, with its partners Rasip1 and, in lymphatic vessels, Afadin, are essential for full development of functional, stable vessels. After blood vessels form, Rap1 is not essential for the adhesive function and normal gross vessel morphology, but plays a major role in endothelial homeostasis by transducing shear stress signals critical for endothelial cell function, as described later.
Angiogenic processes
Rap1 promotes cellular processes underlying angiogenic response, including integrin-mediated adhesion, migration, tube formation [3] , and formation of tip cells at the leading edge of a
KEY POINTS
In endothelium in vivo, Rap1 and its effectors: Rasip1 and, in lymphatic vessels, Afadin, are essential for development of functional, stable vessels.
After blood vessels form, Rap1 is not essential for endothelial barrier or vessel maintenance, but is critical for nitric oxide release, endothelial function, normal blood pressure, and normal life span in mice.
In response to elevated cAMP, Rap1 promotes endothelial barrier tightening by spatially controlling cdc42-and rac-regulated actomyosin cytoskeleton contractility and architecture at cell-cell junctions.
Epac-Rap1 signaling axis offers endothelial barrier protection under pathological conditions of increased vascular leakiness and emerges as a novel therapeutic strategy.
Rap1 is critically required for the formation of endothelial mechanosensing complex and for transmitting endothelial cell responses to shear stress, thereby regulating endothelial cell homeostasis.
developing vascular bed [12, 20] and in endothelial cells in vitro [21] (Fig. 1) . A recent study identified Polo-like kinase 2 (Plk2) as a regulator of VEGFdependent endothelial tip cells progression in zebrafish in vivo and in lamellipodia formation in HUVECs [22] . Plk2, a member of the serine-threonine kinase family containing a conserved polo domain responsible for its localization and involved in regulation of cell cycle, had been previously implicated in promoting Rap1 activity in regulation of synaptic plasticity [23] . Plk2 phosphorylation promotes PDZ-GEF activity toward Rap1 in neurons, and similarly, Plk2 binds to PDZ-GEF to regulate Rap1 localization and activity in endothelial cells during lamellipodia formation, where it is required for angiogenesis in vivo [22] . Interestingly, PDZ-GEF is critical for vessel formation and its deletion leads to early lethality in mice [24] . Therefore, Plk2-PDZ-GEF-Rap1 signaling axis is essential for angiogenesis.
Pathological angiogenesis in the retina
Although a positive regulator of developmental angiogenesis, Rap1's role in pathological angiogenesis appears more complex, as Rap1 is involved in vessel stabilizing and inhibitory processes. Pathological processes of inflammation, oxidation, and angiogenesis in retinal pigmented epithelial (RPE) and choroidal endothelial cells (CECs) underlie the development of neovascular age-related macular degeneration (AMD), a leading cause of blindness in the elderly [25] . Visual acuity loss occurs when activated CECs migrate through Bruch's membrane and across the RPE into the sensory retina to proliferate into choroidal neovascularization (CNV) [26] . Epac-mediated activation of Rap1 in both these cellular compartments leads to decreased CNV. In RPEs, Epac1-dependent Rap1a activation promotes RPE barrier formation by inhibiting NADPH oxidase-generated ROS [27] . By a similar mechanism in CECs, activated Rap1a inhibits NADPH oxidasedependent ROS production induced by proinflammatory stimuli [28] . In both cases, Rap1 exerts these effects by inhibiting Rac1-dependent NADPH oxidase activity. Therefore, activating Rap1a has been proposed as a novel therapeutic approach for AMD [26] .
However, excessive neovascularization of the retina is associated with proliferative retinopathies, FIGURE 1. Rap1 is critical for shear stress sensing, angiogenic responses, and control of endothelial barrier. Rap1, activated by shear stress, is required for nitric oxide production downstream from the mechanosensing complex comprised of PECAM-1, VE-cadherin (VE-CAD), and VEGFR2. By controlling nitric oxide release, Rap1 signaling regulates endothelial homeostasis. Rap1 regulates angiogenic responses by promoting VEGF receptor 2 (VEGFR2) activation in a process dependent on integrin a V b 3 , and as a downstream effector of angiogenic growth factor receptors (FGFR2, S1PR, and VEGFR2); integrin a 5 b 1 is only one of the downstream effectors, others are not shown. Activated by cAMP-dependent GEF, Epac, Rap1 promotes junctional stability via its effectors Rasip1 and Radil (not shown) which, translocated to junctions by Heart-of-Glass (HEG1) receptor, inhibit Rho-mediated Radial Stress Fiber formation, whereas cdc42 and Afadin promote circumferential actin bundle formation increasing junctional stability. Afadin also promotes junctional tightening by mediating attachment between tight and adherens junctions. Other Rap1 effectors, such as Krit1 (not shown), are also involved in this process.
such as diabetic and retinopathy of prematurity (ROP). Studies in junctional adhesion molecule (JAM)-C knockout mice, which negatively regulates Rap1 activation in endothelium [29] , revealed that activation of Rap1 via inhibition of JAM-C, promotes endothelial adhesion. This occurs via integrin b 1 and tip cell formation of vessels in the avascular area and vessel normalization in ROP, and has been proposed as a therapeutic approach for ROP [20] . These studies emphasize context-specific effects of Rap1 on cellular and physiological processes.
NOVEL PHYSIOLOGICAL FUNCTION OF RAP1: REGULATION OF VASCULAR TONE, NITRIC OXIDE RELEASE AND ENDOTHELIAL CELL SHEAR STRESS RESPONSES

Rap1 in endothelium controls vascular tone and nitric oxide release
Our recent analysis of tissue-specific knockout mice revealed that, via separate mechanisms in smooth muscle and endothelium, Rap1 controls vascular tone and is required for maintenance of normal blood pressure [8
We found that total Rap1b-deficiency leads to hypertension and pathological cardiac hypertrophy. We discovered that in smooth muscle, Rap1-deficiency leads to increased contractility under basal conditions and decreased cAMP-dependent relaxation in response to Rap1 activator, Epac1 [30 & ]. Interestingly, we also found that selective deletion of both Rap1 isoforms in endothelium leads to an even more severe phenotype of hypertension, cardiac hypertrophy, and early lethality of male mice, the most severe endothelial phenotype described so far [4] . Endothelium plays a key role in response to increased blood flow by releasing nitric oxide, which leads to vessel relaxation. Defective endothelial release of dilatory nitric oxide in response to elevated blood flow leads to hypertension. We found that deletion of both Rap1 isoforms in endothelium leads to a severe attenuation of nitric oxide release in response to shear stress and severely inhibits nitric oxidedependent vasodilation [8 && ]. Underlying defective nitric oxide release is impaired ability of Rap1-KO endothelial cell to sense shear stress via endothelial junctional mechanosensing complex involving VE-cadherin, as described later. These findings point to a novel, critical role of Rap1 in regulation of endothelial homeostasis, as decreased nitric oxide bioavailability leads to endothelial dysfunction, which is associated with proinflammatory states and underlies the pathogenesis of cardiovascular disease [31] .
Mechanotransduction of shear stress signals from flowing blood
In addition to promoting VEGF-dependent VEGFR2-mediated angiogenic responses and VEGF-dependent VEGFR2 activation [12] , our recent research identified Rap1 as a key regulator of shear stressinduced VEGFR2 activation [8 && ] (Fig. 1) . Essential endothelial cell responses, including nitric oxide release, are significantly regulated by shear stress of flowing blood [32] . The mechanisms of sensing shear stress involve the formation of endothelial mechanosensing complex comprised of PECAM-1, VE-cadherin, and VEGFR2 [33] , which is required for release of nitric oxide, a key regulator of endothelial homeostasis. We found that in response to shear stress, Rap1, activated downstream from PECAM-1, promotes the formation of the mechanosensing complex, VEGFR2 transactivation, association with PI3K and downstream signaling to eNOS activation and nitric oxide production [8 && ] (Fig. 1) . Although the exact molecular details are not fully understood, Afadin-knockout leads to a similar signaling defect in PI3K-VEGFR2 association in endothelial cells, and a defect in postnatal VEGFdependent angiogenesis in vivo [18] . In addition, a mechanism of Rap1-mediated regulation of VEGFR2 downstream signaling to PI3K involving Afadin has been proposed [34] . Mechanistically, this finding establishes a novel paradigm for Rap1 as a regulator of mechanotransduction in endothelial cells that may be applicable to other cell types; as Rap1 activation in response to turbulence has been reported in hematopoietic cells [35] and in response to stretching in permeabilized fibroblasts [36] . Physiological significance of this novel Rap1 function as a regulator of mechanosensing is clinically significant because hemodynamic shear stress is physiologically the most significant nitric oxide inducer. Defects in nitric oxide bioavailability lead to endothelial cell dysfunction, and are associated with cardiovascular disease [37, 38] . Furthermore, defective shear stress sensing in endothelial cell-specific Rap1 knockout embryos may underlie physiologic/hemodynamic abnormality that leads to hemorrhage and lethality [13 & ].
DYNAMIC REGULATION OF ENDOTHELIAL BARRIER
Since the discovery of the effect of activated Rap1 on promoting endothelial cell barrier function [39] [40] [41] [42] , research has focused on the underlying mechanisms, especially in response to elevated cAMP. cAMP, one of the most potent stabilizers of endothelial barrier, acts via Rap1 GEF Epac and PKA in signaling pathways that converge on Rac1 [6, 43, 44 & ] (Fig. 1) . It is now better understood that Rap1 activity is dynamically regulated during different stages of barrier control [5] , via specific GEFs and upstream activators. Once activated Rap1, regulates endothelial barrier function via two major mechanisms: [1] directly via enforcement of VE-cadherin-adhesiveness (Rap1 is also cadherin activated downstream from VE-cadherin) and VE-cadherin-mediated endothelial junction integrity, and [2] indirectly, via dynamic regulation of the actomyosin cytoskeleton and Rho-dependent tension.
Rap1, via discrete effectors spatially controls actomyosin contractility to regulate endothelial barrier Endothelial barrier function is dynamically regulated by rearrangement of the actin cytoskeleton, with circumferential actin bundles (CAB) promoting adherens junction formation and endothelial cell junction tightening, whereas the induction of permeability leads to formation of radial stress fibers (RSF) connected to punctate adherens junctions [45] . The balance between the two types of stress fibers, punctate adherens junctions, generating 'cytoskeletal tension', and CABs attached to linear junctions and dependent on nonmuscle myosin IIB (NM-IIB) binding, generating 'junctional tension' [5] , determines endothelial barrier function. This balance is differentially regulated by external factors; inflammatory stimuli promote RSFs and junction dissociation, whereas factors leading to elevation of membrane-associated cAMP promote CABs. In epithelial cells, NM-IIB localization at cell-cell contacts and CAB formation was shown to be regulated by Rap1 [46] . A similar mechanism was recently implicated in endothelial cells [47 && ,48 && ] . In endothelial cells, Rap1 induces NM-II activation at cell-cell contacts and CAP formation through FGD5-dependent activation of the Cdc42-MRCK pathway. In response to cAMP elevation, Rap1 suppresses NM-II activation by Rho-ROCK pathway, preventing ROCK-dependent RSF induction. This process is mediated by Rap1 effectors Rasip1 and its close relative, a more widely expressed 117 kD Ras-association and dilute domain-containing protein (Radil), originally identified as Rap1a effector in promoting integrin-mediated cell adhesion and migration [49] . Upon Rap1 activation Rasip1 and Radil, via their RA domains associate with Rap1, and with Heart of Glass (HEG1) receptor, which transports them to the plasma membrane [50] , where they form a multimeric complex with RhoGAP ArhGAP29. This, then, inhibits Rho (Fig. 1) . In-vivo phenotype of Rasip1 knockout mice is consistent with the proposed model, with altered junctional actin organization and altered localization of actinbundling protein NM-IIB and junctional remodeling [16 && ].
Rap1 promotes junctional adhesiveness via Afadin
Scaffolding properties of Afadin play a role in connecting actomyosin cytoskeleton to cadherins and between adherens junctions and tight junctions. Afadin, in a Rap1-dependent manner, promotes barrier enhancement by mediating a cross talk between tight junctions and adherens junction by interacting with ZO1-1 and p120-catenin, respectively [52, 53] . Activated by C3G during barrier recovery after thrombin dissolution, Rap1, via Afadin, leads to enhanced interaction between adherens junction proteins VE-cadherin and p120-catenin, stimulating adherens junction reannealing and leading to inhibition of Rho in a Rac1-Rac1 GEF, TIAM-dependent manner [53] (Fig. 1) . Thus, by binding both stress fibers and the cortical actin ring, Afadin acts as an important sensor of mechanical forces reinforcing endothelial cell junctions [54] . In epithelial cells, together with ZO1, Afadin regulates tension and maintains junction architecture in response to changes in contractility [55] .
Rap1 enhances endothelial cell barrier under inflammatory conditions
In-vitro stimulation of Epac1 in cultured endothelial cells promotes barrier tightening and prevents increased permeability in vivo. However, Epac activation does not lead to reduced basal permeability in intact microvessels under normal conditions; strong evidence supports the notion that under resting conditions, cAMP sustains the endothelial barrier primarily via PKA-dependent mechanisms, whereas the Epac pathway is more relevant for stimulated barrier protection [6, 43] . In-vivo studies have revealed the relative role of Rap1 in endothelial cell barrier maintenance in normal and challenged conditions. Although in adult vasculature Rap1 is not essential for endothelial barrier maintenance, as evidenced by normal appearance of endothelial cell junctions in vessels from Rap1-deficient mice [8 && ], Rap1 is important for regulation of endothelial barrier stability under pathophysiological conditions. In-vivo studies have demonstrated the barrier protective role of cAMP-Epac-Rap1a signaling in a mouse model of acute lung injury (ALI) in response to prostacyclin [56] or mechanical injury [57] . Interestingly, this protective function of Rap1a in ALI is mediated by Krev/Rap1 Interaction Trapped 1 (Krit1), a 81 kD multidomain protein encoded by CCM1 gene, and implicated in autosomal forms of cerebral cavernous malformation, a vascular defect responsible for seizures and stroke [58] and previously shown to localize to cell-cell junctions in a Rap1-dependent manner [59] . Therefore, although Krit1, with preferential expression in small vessels with well-defined tight junctions may have distinct from Rap1 functions, particularly during development [4,13 & ]. Rap1a-Krit1 axis may act as potential new target for treatment of acute vascular barrier dysfunction [57] . Epac-Rap1 axis has also been shown to prevent exotoxin-3 endothelial permeability and bacterial transmigration across vascular wall in bacterial infection by Pseudomonas aeruginosa, a leading agent of nosocomial infections [60] . Because most strains are multiresistant to antibiotherapy, targeting the Epac-Rap1 axis may offer an attractive strategy aimed at limiting the action of its major virulence factors.
A converse approach of inhibiting Rap1 has been proposed as a strategy to increase stem cell engraftment in dystrophic muscle [61] . Inhibition of endothelial junctional protein JAM-A was found to promote engraftment of mesoangioblasts, vessel associated-stem cells, by preventing Rap1 activation in Epac1/2-dependent manner. Thus, pharmacological inhibition of JAM-A-Epac-Rap1 signaling may offer a novel strategy for stem-based therapies of muscular dystrophy.
Future directions
Studies in disease models in vivo point to an important role of Rap1 in dynamic regulation of endothelial barrier and vessel integrity and implicate Rap1 with its effectors as potential therapeutic targets. Although most studies have focused on cAMPmediated regulation of Rap1, protective in endothelial barrier, recent discovery of Rap1 as a critical regulator of shear stress-induced responses and nitric oxide release, justify further investigation into the role of Rap1 in pathologies associated with defective shear stress responses and underlying cardiovascular disease [38, 62] . Furthermore, as a positive, upstream regulator of VEGF and shear stress induced VEGFR2 activation and signaling [8 && ,12], Rap1 signaling may be exploited in pathologies associated with abnormal VEGF signaling, such as retinopathies, diabetes, and tumor angiogenesis. In addition to disease-associated conditions, relative importance of the various Rap1 signaling pathways in endothelium is likely to depend on vessel type and location and, therefore, ought to be examined in small and large vessels.
CONCLUSION
Exciting advances have been made in understanding biological functions of Rap1 and their significance in vascular biology. The complexity of Rap1 signaling is becoming unraveled with the identification of specific molecular targets mediating Rap1 responses. Targeting Rap signaling is emerging as a novel therapeutic approach in cardiovascular pathologies associated with retinopathies, inflammation, diabetes, and cancer. Emerging Rap1 function as a critical regulator of endothelial cell shear stress responses justifies further investigation into the role of Rap1 in endothelial dysfunctionassociated cardiovascular pathologies.
